SCN1A

Chr 2AD

sodium voltage-gated channel alpha subunit 1

Also known as: DEE6, DEE6A, DEE6B, DRVT, EIEE6, FEB3, FEB3A, FHM3

Voltage-dependent sodium channels are heteromeric complexes that regulate sodium exchange between intracellular and extracellular spaces and are essential for the generation and propagation of action potentials in muscle cells and neurons. Each sodium channel is composed of a large pore-forming, glycosylated alpha subunit and two smaller beta subunits. This gene encodes a sodium channel alpha subunit, which has four homologous domains, each of which contains six transmembrane regions. Allelic variants of this gene are associated with generalized epilepsy with febrile seizures and epileptic encephalopathy. Alternative splicing results in multiple transcript variants. The RefSeq Project has decided to create four representative RefSeq records. Three of the transcript variants are supported by experimental evidence and the fourth contains alternate 5' untranslated exons, the exact combination of which have not been experimentally confirmed for the full-length transcript. [provided by RefSeq, Oct 2015]

OMIMResearchGenerating clinical summary…
GOF/LOFmechanismADLOEUF 0.075 OMIM phenotypes
VCEP Guidelines: Epilepsy Sodium ChannelReleased
View SpecificationsClinGen Panel
Clinical SummarySCN1A
🧬
Gene-Disease Validity (ClinGen)
generalized epilepsy with febrile seizures plus · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

4 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.07LOEUF
pLI 1.000
Z-score 8.52
OE 0.02 (0.010.07)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?
5.22Z-score
OE missense 0.55 (0.510.59)
590 obs / 1070.7 exp
Constrained

Extremely missense-constrained (top ~0.01%)

Observed / Expected Ratios?
LoF OE?0.02 (0.010.07)
00.351.4
Missense OE?0.55 (0.510.59)
00.61.4
Synonymous OE?0.94
01.21.6
LoF obs/exp: 2 / 88.5Missense obs/exp: 590 / 1070.7Syn Z: 0.88
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveSCN1A-related seizure disordersLOFAD
Mechanism Note (variant-dependent)
GOFLOF— mechanism depends on specific variant

Nav1.1 is the most commonly mutated gene in epilepsy. LOF (truncation, severe missense with loss of current) causes Dravet syndrome via reduced inhibitory interneuron firing. GOF missense variants (increased persistent current) cause GEFS+. Mechanism is variant- and phenotype-dependent.12

This gene — mechanism propensity

DN
0.5477th %ile
GOF
0.79top 25%
LOF
0.53top 25%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and gain-of-function). The Badonyi & Marsh model scores gain-of-function highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports loss-of-function (haploinsufficiency). Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOF1 literature citation · LOEUF 0.07 · ClinGen HI: Sufficient evidence for dosage pathogenicity
GOFprediction above median · 1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFSCN1A mutations alter channel inactivation, resulting in persistent inward sodium current. This gain-of-function abnormality will likely enhance excitability of neuronal membranes by causing prolonged membrane depolarization, a plausible underlying biophysical mechanism responsible for this inherite3
LOFHer early myoclonic seizures were likely due to haploinsufficiency of SCN1A and SCN2A, which are included in the deletion region.4

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

SCN1A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Dravet Syndrome (DS)

A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet Syndrome

RECRUITING
NCT07675746Phase EARLY_PHASE1Second Affiliated Hospital of Guangzhou Medical UniversityStarted 2025-12-22
RC001 injection-Dose Escalation CohortRC001 injection-Fixed Dose Cohort
16P11.2 Deletion Syndrome16p11.2 Duplications1Q21.1 Deletion

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

RECRUITING
NCT01238250Simons SearchlightStarted 2010-10
Dravet Syndrome

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

ACTIVE NOT RECRUITING
NCT06112275Phase PHASE1, PHASE2Encoded TherapeuticsStarted 2024-02-28
ETX101
Dravet Syndrome

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

RECRUITING
NCT05419492Phase PHASE1, PHASE2Encoded TherapeuticsStarted 2024-05-14
ETX101
Dravet Syndrome

Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

RECRUITING
NCT07251673Assistance Publique - Hôpitaux de ParisStarted 2025-09-15
Dravet SyndromeEpilepsy

Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome

ACTIVE NOT RECRUITING
NCT05472389Phase NAHospices Civils de LyonStarted 2022-10-14
Video-electroencephalographyBlood Samples
Dravet Syndrome

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

ACTIVE NOT RECRUITING
NCT06283212Phase PHASE1, PHASE2Encoded TherapeuticsStarted 2024-05-09
ETX101
EpilepsyDravet SyndromeDrug Resistant Epilepsy

A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome

RECRUITING
NCT07013331Phase NAHospices Civils de LyonStarted 2026-05-04
[18F]MPPF PET-MRI

Paralog Hotspots

SCN1A / SCN2A / SCN8A

Positions in SCN1A where a homologous residue in SCN1A / SCN2A / SCN8A has at least one curated Pathogenic or Likely pathogenic variant in ClinVar. A tick here suggests a residue worth scrutinizing when interpreting a VUS in SCN1A.
12009
Hover a tick to see the residue position.
hit in 1 paralog hit in both paralogs356 hotspots · data: scn-meta.json